Squarepoint’s AC Immune ACIU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-12,642
Closed -$25.7K 4308
2025
Q2
$25.7K Sell
12,642
-9,764
-44% -$17K ﹤0.01% 4373
2025
Q1
$41.9K Sell
22,406
-21,378
-49% -$53.9K ﹤0.01% 4370
2024
Q4
$118K Buy
+43,784
New +$137K ﹤0.01% 4656
2023
Q3
Sell
-11,036
Closed -$32.6K 3727
2023
Q2
$32.6K Buy
+11,036
New +$24.1K ﹤0.01% 3469
2021
Q2
Sell
-18,925
Closed -$144K 3164
2021
Q1
$144K Sell
18,925
-30,303
-62% -$216K ﹤0.01% 2806
2020
Q4
$255K Buy
+49,228
New +$251K ﹤0.01% 2338
2020
Q2
Sell
-13,860
Closed -$96K 2183
2020
Q1
$96K Buy
+13,860
New +$108K ﹤0.01% 1646
2019
Q1
Sell
-12,800
Closed -$121K 2107
2018
Q4
$121K Buy
+12,800
New +$121K ﹤0.01% 1780

Other funds holding ACIU

Squarepoint's ACIU Position: Q3 2025 in Review

Squarepoint sold out of AC Immune (ACIU) in Q3 2025, closing a stake of 12,642 shares — an estimated $25.7K sold.

Squarepoint first reported a position in ACIU in Q4 2018 and held it in 8 quarters. The position peaked at $255K in Q4 2020. 40 funds tracked by Wall St. Rank hold ACIU as of Q3 2025.

  • Squarepoint reported no remaining AC Immune position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 12,642 AC Immune shares in Q3 2025, an estimated $25.7K.
  • Squarepoint first reported a position in AC Immune in Q4 2018 and held it in 8 quarters.
  • Squarepoint's AC Immune position peaked at $255K in Q4 2020.
  • 40 funds tracked by Wall St. Rank held AC Immune as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.